Corbus Pharmaceuticals Holdings, Inc.
CRBPHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeCorbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. The $166.4M market capitalization puts CRBP squarely in micro-cap range for its industry. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
Market Cap
$166.4M
Beta
2.56
P/E (TTM)
—
P/E (Fwd)
-1.77
EPS (TTM)
$-5.80
EPS (Fwd)
$-5.08
ROE
-66.7%
ROA
-39.5%
Cash
$138.2M
Total Debt
$1.2M
Free CF
-$43.3M
52W Change
3.2%
Annual Financials
Cash vs Debt
Where CRBP stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, CRBP finished 0.78% above its 150-day moving average ($8.96) and 10.77% below its 200-day moving average ($10.12). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CRBP overbought or oversold?
At the July 15, 2026 close, CRBP's RSI(14) was 58.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Corbus Pharmaceuticals Holdings, Inc. holds $138.2M in cash against $1.2M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$43.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -66.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 2.56 means CRBP is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CRBP.